SOURCE: iPharma, Ltd.

iPharma, Ltd. Logo

September 20, 2016 05:00 ET

iPharma Announces Inhalation Product Development and Testing Services

International Inhalation Center of Excellence

SAN FRANCISCO, CA and HONG KONG, CHINA--(Marketwired - September 20, 2016) - iPharma Limited, a privately held, global pharmaceutical contract research organization, announced today that it is providing inhalation product design, development, and testing services that encompass feasibility to commercial stage support. The company was founded by a team of world renowned experts in inhalation product development with decades of experience with leading edge inhalation technologies and in the development of products for the US and European regulatory bodies. iPharma offers three core services:

  • Formulation development: Pre-formulation (dry powder, liquid, or suspension-based), particle engineering via spray drying.
  • Inhaler development: Support of inhaler design and modeling
  • Inhalation product testing: Feasibility, development, and commercial services.
    • Feasibility services: pre-formulation screening and device testing & selection
    • Development services: Product development and characterization, method development and validation, clinical release testing, and product registration support
    • Commercial services: Process validation and commercial product release testing services

iPharma limited has two sites: Hong Kong Science Park headquarters/R&D facility and Brisbane, California R&D/GMP facility.

"Today there is a global explosion in the development of new inhaled medicines for both lung and systemic diseases, and this presents a business opportunity and demand for expertise that ensures the right formulation and device are matched for delivery to the lungs," stated Keith Ung PhD, President of iPharma. "Respiratory product development is complex and care should be taken to ensure accurate, consistent dosing in a patient-friendly format."

iPharma began operations in 2016, is currently serving pharmaceutical company clients in the US, and is soon to begin services in Asia. iPharma's goal is to become the world's leading inhalation development contract research organization.


All statements other than statements of historical fact included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. We have based these forward-looking statements upon information available to management as of the date of this release and management's expectations and projections about certain future events. It is possible that the assumptions made by management for purposes of such statements may not materialize. Actual results may differ materially from those projected or implied in any forward-looking statements.

Contact Information